Amylyx Pharmaceuticals
Developing avexitide-led therapies for endocrine and neurodegenerative diseases.
Something off on this page? Send us feedback.
Profile
Develops clinical-stage therapies for endocrine and neurodegenerative diseases, led by avexitide in post-bariatric hypoglycemia. With RELYVRIO/ALBRIOZA withdrawn, the business is centered on pipeline execution rather than commercial sales.
Develops drug candidates for endocrine conditions and neurodegenerative diseases, with avexitide at the center of the current pipeline after the withdrawal of RELYVRIO/ALBRIOZA from the US and Canadian markets.
Current work is concentrated in clinical development rather than commercial sales. Avexitide targets post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery, while AMX0035, AMX0114, and AMX0318 keep the pipeline tied to rare endocrine and neurodegenerative indications.
Execution depends on late-stage trial results, regulatory review, and rebuilding around acquired avexitide assets after the PHOENIX ALS trial failed its endpoints. Operations are centered in Cambridge, with founder co-CEOs still running the company.
Company facts
Key statistics
Year to date +204% · Average volume (30d) 3.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 27, 2026 | Guggenheim | Target | $55 | $57 | |
| Aug 19, 2026 | Guggenheim | Reiterate | Buy | $40 | $55 |
| Aug 18, 2026 | Mizuho Securities | Target | $30 | $42 | |
| Aug 18, 2026 | Robert W. Baird | Target | $28 | $52 | |
| Aug 18, 2026 | H.C. Wainwright | Reiterate | Buy | $34 | $55 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.36 | −$0.39 | −8.1% | — | — | — | +10.71% |
| May 7, 2026Q1 FY26 | −$0.34 | −$0.37 | −8.8% | — | — | — | −3.09% |
| Mar 3, 2026Q4 FY25 | −$0.31 | −$0.30 | +3.2% | −$52.0K | — | — | +6.66% |
| Nov 6, 2025Q3 FY25 | −$0.43 | −$0.37 | +14.0% | $52.0K | — | — | −1.20% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$22.1M | −$141.0K | −$19.9M | −$108.0K | −$98.0K | $0 | |
| Operating income | −$37.8M | −$42.9M | −$36.0M | −$36.6M | −$43.8M | −$45.7M | |
| Net income | −$35.9M | −$41.4M | −$34.4M | −$33.0M | −$41.3M | −$43.4M | |
| Diluted EPS | −$0.42 | −$0.46 | −$0.37 | −$0.28 | −$0.37 | −$0.39 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $22.2M · FY23 $380.8M · FY24 $87.4M · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $250.8M · Total debt $5.3M · Total assets $264.6M · Shareholders' equity $239.2M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 111.19M · Float 82.38M · 74.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 16.73M | 15.04% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 8.83M | 7.94% | 13F | Aug 7, 2026 |
| Perceptive Advisors LLC | 8.33M | 7.50% | 13F | Aug 14, 2026 |
| TCG Crossover Management, LLC | 6.24M | 5.62% | 13F | Aug 14, 2026 |
| Commodore Capital LP | 5.65M | 5.08% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 10, 2026 | Gina Mazzariello | officer: Chief Legal Officer | −15,000 | $17.61 |
| Jul 9, 2026 | Gina Mazzariello | officer: Chief Legal Officer | −15,000 | $18.32 |
| May 21, 2026 | Karen Firestone | director | +3,800 | $13.51 |
| Mar 2, 2026 | Gina Mazzariello | officer: Chief Legal Officer | −6,844 | $14.52 |
| Mar 2, 2026 | James M. Frates | officer: Chief Financial Officer | −7,909 | $14.52 |
Peers
- Rezolute
Late-stage hyperinsulinism rival in rare hypoglycemia
- Xeris Biopharma
Commercial endocrine peer with glucagon and rare-disease reach
- Biogen
ALS incumbent with QALSODY and neurology development scale
- Ionis Pharmaceuticals
RNA-focused ALS competitor with genetic neurology programs
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals | $34.85 | +0.35% | $3.86B | — | — | — | — |
| Rezolute | $4.65 | +0.65% | $444.9M | — | — | — | — |
| Xeris Biopharma | $8.48 | +0.06% | $1.46B | — | 47.8 | 4.4 | +27.2% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Median | 38.7 | 32.2 | 4.4 | +3.4% |